# RAB42

## Overview
RAB42 is a gene that encodes a member of the RAS oncogene family, specifically a small GTPase protein known as RAB42. This protein is involved in intracellular vesicle trafficking, a critical process for maintaining cellular homeostasis and function. As a member of the RAS superfamily, RAB42 plays a role in various cellular processes, including signal transduction and membrane transport. The protein's function is particularly significant in the context of cancer biology, where its altered expression has been linked to tumor progression and poor prognosis in several cancer types, such as glioma and hepatocellular carcinoma. The RAB42 protein's involvement in pathways like VEGF signaling and its association with immune regulation highlight its potential as a therapeutic target and biomarker in oncology (Liu2021RAB42; Peng2022RAB42; Zheng2022PanCancer).

## Clinical Significance
The RAB42 gene has been implicated in various cancers due to its altered expression levels. In glioma, particularly glioblastoma, RAB42 is significantly upregulated and associated with poor prognosis. It promotes glioma pathogenesis through the VEGF signaling pathway, contributing to tumor growth and angiogenesis. High RAB42 expression correlates with worse survival outcomes, making it a potential prognostic marker and therapeutic target in glioma (Liu2021RAB42; Sun2022The).

In hepatocellular carcinoma (HCC), RAB42 is also overexpressed and linked to poor clinical outcomes. Its expression is associated with various clinical parameters, including tumor stage and histologic grade. Genetic alterations of RAB42, although infrequent, are associated with poor survival. The gene's hypomethylation may contribute to its overexpression, influencing immune-related pathways and the tumor microenvironment (Peng2022RAB42).

Pan-cancer analyses reveal that RAB42 is upregulated in several other tumor types, including kidney and lung cancers. Its expression correlates with immune cell infiltration and immune checkpoint gene expression, suggesting a role in immune regulation and potential as a biomarker for immunotherapy efficacy (Zheng2022PanCancer).


## References


[1. (Liu2021RAB42) Baoling Liu, Quanping Su, Bolian Xiao, Guodong Zheng, Lizhong Zhang, Jiawei Yin, Lijuan Wang, Fengyuan Che, and Xueyuan Heng. Rab42 promotes glioma pathogenesis via the vegf signaling pathway. Frontiers in Oncology, November 2021. URL: http://dx.doi.org/10.3389/fonc.2021.657029, doi:10.3389/fonc.2021.657029. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2021.657029)

[2. (Peng2022RAB42) Hao Peng, Xuanlong Du, and Yewei Zhang. Rab42 is a potential biomarker that correlates with immune infiltration in hepatocellular carcinoma. Frontiers in Molecular Biosciences, May 2022. URL: http://dx.doi.org/10.3389/fmolb.2022.898567, doi:10.3389/fmolb.2022.898567. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fmolb.2022.898567)

[3. (Sun2022The) Liwei Sun, Tao Yan, and Bing Yang. The progression related gene rab42 affects the prognosis of glioblastoma patients. Brain Sciences, 12(6):767, June 2022. URL: http://dx.doi.org/10.3390/brainsci12060767, doi:10.3390/brainsci12060767. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/brainsci12060767)

[4. (Zheng2022PanCancer) Mingzhu Zheng, Wenhao Wang, Yulan Bu, Jing Liu, Jingang Ma, Rui Wang, Xiaomin Ren, Zhong Lu, Jiaqiu Li, and Jinwei Cai. Pan-cancer analysis of the roles and driving forces of rab42. Biomolecules, 13(1):43, December 2022. URL: http://dx.doi.org/10.3390/biom13010043, doi:10.3390/biom13010043. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/biom13010043)